Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Isovaleric acid [503-74-2]

Isovaleric acid [503-74-2]

Stampa Stampa
Entra
Ordine minimo 2

Cat# HY-W012980-100mg

Size : 100mg

Marca : MedChemExpress


Description

Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders[1][2][3][4].

IC50 & Target

Microbial Metabolite

 

Human Endogenous Metabolite

 

In Vitro

Isovaleric acid (5.0 mM, 1 h) reduces Na+, K+-ATPase activity in synaptic membranes from cerebral cortex of Wistar rats (40 days old)[2].
Isovaleric acid (200 μM, 5 days) inhibits RANKL (Receptor Activator of Nuclear Factor κB Ligand)-induced osteoclast (OC) differentiation by promoting AMPK phosphorylation[3].
Isovaleric acid (200 μM, 3 days) has an inhibitory effect on the expression of osteoclast (OC)-related genes[3].
Isovaleric acid (1-100 μM, 1 or 5 min) alleviates acetylcholine-induced colonic smooth muscle contraction by activating the cAMP/PKA pathway[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Isovaleric acid Related Antibodies

Western Blot Analysis[3]

Cell Line: RANKL (Receptor Activator of Nuclear Factor κB Ligand) -induced multinucleated osteoclasts (OCs) (Derived from mouse bone marrow-derived macrophages (BMDMs))
Concentration: 200 μM
Incubation Time: 3 or 5 days
Result: Inhibited the protein expression of OC-related protein such as RANK, TRAF6, NFATc1 and c-fos.
Upregulated the expression of phosphorylated AMPK.

Real Time qPCR[3]

Cell Line: RANKL (Receptor Activator of Nuclear Factor κB Ligand) -induced multinucleated osteoclasts (OCs) (Derived from mouse bone marrow-derived macrophages (BMDMs))
Concentration: 200 μM
Incubation Time: 3 days
Result: Significantly decreased the expression of OC-related genes including RANK, Blimp1, TRAF6, c-fos and NFATc1.
Downregulated the expression of fusogenic genes including OC-STAMP, DC-STAMP and Atp6v0d2.
In Vivo

Isovaleric acid (administered via drinking water at 75 or 150 mM, once daily for 32 days) ameliorates ovariectomy-induced osteoporosis in an ovariectomized mouse model by inhibiting osteoclast (OC) differentiation[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Ovariectomy (OVX)-induced osteoporosis C57BL/6 mice model (8 weeks old)[3]
Dosage: 75 or 150 mM
Administration: Oral gavage (p.o.) (Isovaleric acid was added to drinking water), once daily for 32 days
Result: Reduced weight gain in Ovariectomy (OVX)-induced osteoporosis C57BL/6 mice, enhanced the expression of OC-related genes, including NFATc1, Ctsk, and TRAP, and decreased the pore area in bone tissue.
Masse moléculaire

102.13

Formule

C5H10O2
CAS No.
Appearance

Liquid (Density: 0.926 g/cm3)

Color

Colorless to light yellow

SMILES

CC(C)CC(O)=O
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

H2O : 100 mg/mL (979.14 mM; Need ultrasonic)

DMSO : 100 mg/mL (979.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 9.7914 mL 48.9572 mL 97.9144 mL
5 mM 1.9583 mL 9.7914 mL 19.5829 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (24.48 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (24.48 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (979.14 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureté et documentation
Références

Si può anche essere interessati nei seguenti prodotti:



Cat#
Descrizione
Cond.
Priced
NB-42-41410-25g
Valeric acid [109-52-4]
 25g 
NB-42-41410-100g
Valeric acid [109-52-4]
 100g